SCHEMBL1444085

SCHEMBL1444085

CC(=O)Oc1cc2c(s1)CCNC2

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PNMT P11086 6/20 0.61
TPSAB1 Q15661 1/20 0.41
TPSD1 Q9BZJ3 1/20 0.41
TPSG1 Q9NRR2 1/20 0.41
ITGB3 P05106 5/20 0.38
ITGA2B P08514 5/20 0.38
ABCB11 O95342 1/20 0.38
CHRM2 P08172 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
AR P10275 1/20 0.38
OPRM1 P35372 1/20 0.38
P2RY12 Q9H244 1/20 0.38
PARP1 P09874 3/20 0.37
PARP2 Q9UGN5 3/20 0.37
KCNH2 Q12809 1/20 0.37
F10 P00742 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1443367 0.98 PNMT (0.60) PNMTTPSAB1TPSD1TPSG1ITGB3
SCHEMBL4058720 0.85 PNMT (0.46) PNMTTPSAB1TPSD1TPSG1ABCB11
SCHEMBL18822929 0.84 PNMT (0.54) PNMTTPSAB1TPSD1TPSG1ITGB3
SCHEMBL9471965 0.84 PNMT (0.54) PNMTTPSAB1TPSD1TPSG1ITGB3
SCHEMBL15071934 0.84 PNMT (0.54) PNMTTPSAB1TPSD1TPSG1ITGB3
Hydrochloric Acid SCHEMBL14141606 0.83 PNMT (0.52) PNMTTPSAB1TPSD1TPSG1ITGB3
SCHEMBL30536685 0.80 PNMT (0.49) PNMTTPSAB1TPSD1TPSG1ITGB3
SCHEMBL4397849 0.79 PNMT (0.61) PNMTTPSAB1TPSD1TPSG1ITGB3
SCHEMBL11289658 0.79 PNMT (0.47) PNMTTPSAB1TPSD1TPSG1ITGB3
SCHEMBL1038858 0.76 PNMT (0.56) PNMTTPSAB1TPSD1TPSG1ITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109311907-B Preparation method of high-purity prasugrel 吉瑞工厂 2022-09-13 CN claimed
WO-2011029456-A1 A PROCESS FOR MAKING PRASUGREL AND ITS INTERMEDIATES SYNTHON BV (NL) 2011-03-17 WO claimed
CN-109311907-B Preparation method of high-purity prasugrel 吉瑞工厂 2022-09-13 CN disclosed
US-10000506-B2 Optically active 2-hydroxy tetrahydrothienopyridine derivatives, preparation method and use in manufacture of medicament thereof JIANGSU VCARE PHARMATECH CO., LTD. (CN) 2018-06-19 US disclosed
US-10000506-B2 Optically active 2-hydroxy tetrahydrothienopyridine derivatives, preparation method and use in manufacture of medicament thereof JIANGSU VCARE PHARMATECH CO., LTD. (CN) 2018-06-19 US disclosed
EP-2532668-B1 OPTICALLY ACTIVE 2-HYDROXY TETRAHYDROTHIENOPYRIDINE DERIVATIVES, PREPARATION METHOD AND USE IN MANUFACTURE OF MEDICAMENT THEREOF JIANGSU VCARE PHARMATECH CO LTD (CN) 2017-05-24 EP disclosed
US-20170121341-A1 OPTICALLY ACTIVE 2-HYDROXY TETRAHYDROTHIENOPYRIDINE DERIVATIVES, PREPARATION METHOD AND USE IN MANUFACTURE OF MEDICAMENT THEREOF JIANGSU VCARE PHARMATECH CO., LTD. (CN) 2017-05-04 US disclosed
US-20170121341-A1 OPTICALLY ACTIVE 2-HYDROXY TETRAHYDROTHIENOPYRIDINE DERIVATIVES, PREPARATION METHOD AND USE IN MANUFACTURE OF MEDICAMENT THEREOF JIANGSU VCARE PHARMATECH CO., LTD. (CN) 2017-05-04 US disclosed
US-9169265-B2 Process for preparing pharmaceutical compounds and intermediate compounds EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) 2015-10-27 US disclosed
US-9169265-B2 Process for preparing pharmaceutical compounds and intermediate compounds EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) 2015-10-27 US disclosed
US-20130030183-A1 PROCESS FOR PREPARING A PHARMACEUTICAL COMPOUND EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) 2013-01-31 US disclosed
WO-2011029456-A1 A PROCESS FOR MAKING PRASUGREL AND ITS INTERMEDIATES SYNTHON BV (NL) 2011-03-17 WO disclosed
US-20100261908-A1 PROCESSES FOR THE PREPARATION OF PRASUGREL , AND ITS SALTS AND POLYMORPHS DR. REDDY'S LABORATORIES LTD. (IN) 2010-10-14 US disclosed
US-20100261908-A1 PROCESSES FOR THE PREPARATION OF PRASUGREL , AND ITS SALTS AND POLYMORPHS DR. REDDY'S LABORATORIES LTD. (IN) 2010-10-14 US disclosed
US-20100179184-A1 ARTICLE OF MANUFACTURE FOR PRASUGREL ELI LILLY AND COMPANY 2010-07-15 US disclosed
US-20100179184-A1 ARTICLE OF MANUFACTURE FOR PRASUGREL ELI LILLY AND COMPANY 2010-07-15 US disclosed
EP-2205611-A2 PROCESSES FOR THE PREPARATION OF PRASUGREL, AND ITS SALTS AND POLYMORPHS Dr. Reddy's Laboratories Ltd. (IN) 2010-07-14 EP disclosed
WO-2009122440-A1 PROCESS FOR THE PREPARATION OF 2-ACETOXY-5-(α -CYCLOPRPYLCARBONYL -2-FLUOROBENZYL)-4,5,6,7-TETRAHYDROTHIENO[3,2-C]PYRIDINE TORRENT PHARMACEUTICALS LTD. (IN) 2009-10-08 WO disclosed
WO-2009062044-A2 PROCESSES FOR THE PREPARATION OF PRASUGREL, AND ITS SALTS AND POLYMORPHS DR. REDDY'S LABORATORIES LTD. (IN) 2009-05-14 WO disclosed
US-20080176893-A1 Formulation of a Thienopyridine Platelet Aggregation Inhibitor ELI LILLY AND COMPANY (US) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10000506-B2 Optically active 2-hydroxy tetrahydrothienopyridine derivatives, preparation method and use in manufacture of medicament thereof TFPI, DHPS, THPO PNMT 172/4885TPSAB1 141/4885TPSD1 125/4885
US-20130030183-A1 PROCESS FOR PREPARING A PHARMACEUTICAL COMPOUND CYP3A5, CYP2C19, CYP4B1 PNMT 1623/4885TPSAB1 246/4885TPSD1 610/4885
US-20080176893-A1 Formulation of a Thienopyridine Platelet Aggregation Inhibitor TBXA2R, THPO, PFKP PNMT 372/4885TPSAB1 105/4885TPSD1 228/4885
US-20100261908-A1 PROCESSES FOR THE PREPARATION OF PRASUGREL , AND ITS SALTS AND POLYMORPHS PFKP, CYP2C19, CYP2C9 PNMT 3754/4885TPSAB1 1704/4885TPSD1 1443/4885
US-20170121341-A1 OPTICALLY ACTIVE 2-HYDROXY TETRAHYDROTHIENOPYRIDINE DERIVATIVES, PREPARATION METHOD AND USE IN MANUFACTURE OF MEDICAMENT THEREOF TFPI, DHPS, THPO PNMT 172/4885TPSAB1 141/4885TPSD1 125/4885
US-20100179184-A1 ARTICLE OF MANUFACTURE FOR PRASUGREL PFKP, PTGIS, P2RY6 PNMT 3136/4885TPSAB1 2097/4885TPSD1 2279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.